$PMCB PharmaCyte is laying the grounds for its clinical trials with pancreatic #cancer. PMCB
To that end, we have restructured our agreement with Austrianova to strengthen our partnership. PharmaCyte CEO Kenneth Waggoner says, “We felt that securing the right of first refusal now was imperative as we move forward with our planned clinical trial in locally advanced pancreatic cancer.”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.